All In Biotech

Drug Trial Radar · NCT05942001

Study of HRS-5041 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HRS-5041 in Subjects With Metastatic Castration-resistant Prostate Cancer

Last checked: Nov 20, 2026Latest source record: Aug 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Aug 3, 2023

Primary completion

Sep 2026

Study completion Sep 2026

Sponsor

Sponsor type
Industry
First posted
Jul 12, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety, tolerability and preliminary efficacy of HRS-5041 in men with progressive metastatic castration resistant prostate cancer. The objective of this study was to determine the dose-limiting toxicity, maximum tolerance and recommended dose of HRS-5041 in phase II study.

Conditions

  • Advanced Prostate Cancer

Interventions

  • HRS-5041Drug

    HRS-5041 was given oral administration, qd, at a 28-day cycle. Patients may continue to use HRS-5041 until disease progression or unacceptable toxicity occurs.

  • Docetaxel injectionDrug

    Docetaxel injection.

  • Abiraterone acetate tabletsDrug

    Abiraterone Acetate tablets.

  • Prednisone Acetate TabletsDrug

    Prednisone Acetate tablets.

  • Enzalutamide Soft CapsulesDrug

    Enzalutamide Soft capsules.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-limiting toxicity (DLT)Time frame: Up to 28 days
  2. Maximum tolerated dose (MTD)Time frame: Up to 28 days
  3. Recommended Phase 2 Dose (RP2D) of HRS-5041Time frame: Up to 28 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Jiaotong University School of Medicine, Renji Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.